Abbott Laboratories ABT exited the first quarter of 2023 with better-than-expected earnings and revenues. The Medical Device segment of ABT registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. The Diabetes Care business continued to benefit from the growing sales of its sensor-based continuous glucose monitoring system, FreeStyle Libre.